…
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Kura Oncology is a clinical-stage biopharmaceutical company developing targeted small-molecule therapies for genomically defined cancers, with programs in hematologic malignancies and select solid tumors. Long-term growth drivers include clinical progress of lead candidates, potential regulatory approvals in genetically defined populations, and partnerships that could support late-stage development and commercialization. Investors may find the company attractive because successful clinical outcomes could provide therapies for unmet needs and increase strategic value.
The primary investment risks are clinical trial failures or delays, regulatory setbacks, the need for additional financing given limited or no commercial revenue, safety issues, and intense competition from other oncology developers.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -135.84M | -130.47M | -89.62M | -63.14M | -60.45M |
| Net income | -136.07M | -129.91M | -89.43M | -63.14M | -60.45M |
| Selling general administrative | 47.05M | 46.54M | 31.50M | 19.65M | 16.10M |
| Gross profit | - | - | - | - | 0.00M |
| Reconciled depreciation | 0.76M | 0.56M | 0.19M | 0.00M | 0.01M |
| Ebit | -140.62M | -131.82M | -92.09M | -63.14M | -62.89M |
| Ebitda | -139.87M | -131.26M | -91.90M | -67.48M | -62.88M |
| Depreciation and amortization | 0.76M | 0.56M | 0.19M | - | 0.01M |
| Non operating income net other | 4.25M | 1.21M | 2.85M | 4.92M | 3.41M |
| Operating income | -140.62M | -131.82M | -92.09M | -67.48M | -62.88M |
| Other operating expenses | 139.87M | 131.26M | 91.90M | 67.48M | 62.88M |
| Interest expense | 0.23M | 0.41M | 0.58M | 0.58M | 0.97M |
| Interest income | 4.25M | 1.21M | 2.80M | 4.67M | 3.17M |
| Net interest income | 4.03M | 0.79M | 2.22M | 4.09M | 2.20M |
| Income tax expense | 0.23M | -0.56M | -0.19M | -4.92M | 3.41M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 139.87M | 131.26M | 91.90M | 67.48M | 62.88M |
| Cost of revenue | - | - | - | - | 0.00M |
| Total other income expense net | 4.78M | 1.35M | 2.47M | 4.34M | 2.44M |
| Net income from continuing ops | -135.84M | -130.47M | -89.62M | -63.14M | -60.45M |
| Net income applicable to common shares | -135.84M | -130.47M | -89.62M | -63.14M | -60.45M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 448.94M | 456.31M | 534.05M | 647.21M | 241.97M |
| Other current assets | 5.72M | 8.44M | 4.33M | 3.97M | 2.68M |
| Total liab | 51.66M | 36.03M | 27.44M | 36.31M | 23.19M |
| Total stockholder equity | 397.27M | -568.81M | -432.97M | -302.50M | -212.88M |
| Other current liab | 31.46M | 20.21M | 16.96M | 18.18M | 11.79M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -721.44M | -568.81M | -432.97M | -302.50M | -212.88M |
| Other liab | - | 0.27M | 0.38M | 0.40M | 0.38M |
| Other assets | - | 3.50M | 3.52M | 7.90M | 2.09M |
| Cash | 37.32M | 51.80M | 90.67M | 325.49M | 26.14M |
| Total current liabilities | 35.26M | 24.06M | 22.45M | 26.02M | 15.56M |
| Net debt | -20.12M | -37.78M | -83.80M | -310.52M | -18.64M |
| Short term debt | 1.51M | 2.32M | 2.26M | 5.09M | 0.25M |
| Short long term debt | - | - | - | 3.00M | 0.25M |
| Short long term debt total | 17.20M | 14.02M | 6.88M | 14.98M | 7.50M |
| Other stockholder equity | 1119.98M | 8.03M | 1.78M | -0.05M | -0.34M |
| Property plant equipment | - | 2.54M | 2.67M | 2.02M | 0.28M |
| Total current assets | 432.48M | 446.43M | 522.29M | 637.29M | 239.60M |
| Net tangible assets | - | 420.28M | 506.61M | 610.90M | 218.78M |
| Short term investments | 386.64M | 386.18M | 427.29M | 307.83M | 210.76M |
| Net receivables | 2.80M | 0.90M | 1.40M | - | 0.03M |
| Long term debt | 9.33M | 9.16M | - | 4.25M | 7.25M |
| Accounts payable | 2.30M | 1.53M | 3.24M | 2.75M | 3.53M |
| Accumulated other comprehensive income | -1.27M | -8.03M | -1.79M | 0.05M | 0.33M |
| Common stock total equity | - | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings total equity | - | -568.81M | -432.97M | -302.50M | -212.88M |
| Non currrent assets other | 7.40M | 3.50M | 3.52M | 1.56M | 2.33M |
| Non current assets total | 16.45M | 9.88M | 11.76M | 9.92M | 2.37M |
| Capital lease obligations | 7.87M | 4.87M | 6.88M | 7.73M | - |
| Long term debt total | - | 9.16M | - | 4.25M | 7.25M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 32.63M | -125.69M | -97.77M | -46.33M | -79.30M |
| Change to liabilities | -0.62M | -2.54M | 5.89M | 1.07M | 0.25M |
| Total cashflows from investing activities | 32.63M | -126.83M | -99.94M | -46.33M | -79.30M |
| Net borrowings | 9.43M | -7.86M | -0.25M | -0.25M | -0.62M |
| Total cash from financing activities | 38.56M | -3.44M | 469.33M | 111.10M | 132.64M |
| Change to operating activities | -2.18M | -0.71M | 0.71M | -0.99M | -0.73M |
| Net income | -135.84M | -130.47M | -89.62M | -63.14M | -60.45M |
| Change in cash | -38.87M | -234.82M | 299.57M | 10.02M | 4.69M |
| Begin period cash flow | 90.88M | 325.70M | 26.14M | 16.12M | 11.43M |
| End period cash flow | 52.01M | 90.88M | 325.70M | 26.14M | 16.12M |
| Total cash from operating activities | -110.06M | -104.55M | -69.83M | -54.76M | -48.66M |
| Issuance of capital stock | 24.72M | 0.00M | 459.33M | 108.17M | 132.17M |
| Depreciation | 0.76M | 0.56M | 0.19M | -1.10M | 0.01M |
| Other cashflows from investing activities | - | - | - | -46.33M | -79.30M |
| Change to inventory | - | - | - | - | -0.44M |
| Change to account receivables | - | - | - | 0.21M | -0.01M |
| Sale purchase of stock | 29.14M | - | 459.33M | 108.17M | 132.17M |
| Other cashflows from financing activities | 13.84M | 3.81M | 10.25M | 2.94M | 1.72M |
| Change to netincome | 26.39M | 24.19M | 12.81M | 9.41M | 9.15M |
| Capital expenditures | 0.63M | 1.15M | 2.17M | 2.17M | 2.17M |
| Change receivables | - | - | - | 0.21M | -0.01M |
| Cash flows other operating | -2.36M | -0.69M | 0.49M | -1.20M | 4.14M |
| Cash and cash equivalents changes | -38.87M | -234.82M | 299.57M | 10.02M | 4.69M |
| Change in working capital | -2.98M | -3.22M | 6.38M | 0.07M | 4.38M |
| Stock based compensation | 26.32M | 23.58M | 12.81M | 9.41M | 8.65M |
| Other non cash items | 1.68M | 0.40M | 0.41M | -1.10M | 0.18M |
| Free cash flow | -110.69M | -105.70M | -72.00M | -54.76M | -48.66M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology Inc |
0.39 5.43% |
7.47 | - | - | - | 3.73 | -7.16 |
| NVO Novo Nordisk A/S |
-0.99 2.39% |
40.60 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-3.90 0.73% |
533.89 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
5.36 0.56% |
957.76 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.
12730 High Bluff Drive, San Diego, CA, United States, 92130
858 500 8800
142
| Name | Title | Year Born |
|---|---|---|
| Dr. Troy Edward Wilson J.D., Ph.D. | Chairman, CEO, Pres & Principal Financial Officer | 1969 |
| Ms. Kathleen Ford | Chief Operating Officer | 1947 |
| Dr. Marc Grasso M.D. | Advisor | 1974 |
| Ms. Kirsten Flowers | Chief Commercial Officer & Chief Corp. Strategy Officer | 1975 |
| Dr. Stephen Dale M.D. | Chief Medical Officer | 1972 |
| Mr. Thomas Doyle | Principal Accounting Officer & Sr. VP of Fin. and Accounting | 1971 |
| Mr. Pete De Spain | Sr. VP of Investor Relations & Corp. Communications | NA |
| Mr. James E. Basta J.D., Esq. | Chief Compliance Officer & Corp. Sec. | 1966 |
| Ms. Teresa Brophy Bair Esq., J.D. | Chief Legal Officer & Corp. Sec. | 1971 |
| Dr. Roger Bakale Ph.D. | VP and Head of CMC, Clinical & Commercial Manufacturing | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.